APA (7th ed.) Citation

SN, A., MM, K., AD, M., SE, K., VV, P., AO, I., . . . AG, I. (2021). CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 23(4), 874. https://doi.org/10.1007/s12094-020-02481-w

Chicago Style (17th ed.) Citation

SN, Aleksakhina, Kramchaninov MM, Mikushina AD, Kubrina SE, Petkau VV, Ivantsov AO, Moiseyenko VM, Imyanitov EN, and Iyevleva AG. "CCND1 and FGFR1 Gene Amplifications Are Associated with Reduced Benefit from Aromatase Inhibitors in Metastatic Breast Cancer." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23, no. 4 (2021): 874. https://doi.org/10.1007/s12094-020-02481-w.

MLA (9th ed.) Citation

SN, Aleksakhina, et al. "CCND1 and FGFR1 Gene Amplifications Are Associated with Reduced Benefit from Aromatase Inhibitors in Metastatic Breast Cancer." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 23, no. 4, 2021, p. 874, https://doi.org/10.1007/s12094-020-02481-w.